GSK (GSK) Competitors

$50.57 +0.19 (+0.38%)

Closing price 05/6/2026 03:59 PM Eastern

Extended Trading

$51.16 +0.59 (+1.17%)

As of 06:14 AM Eastern

GSK vs. AZN, NVS, NVO, SNY, and TAK

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Astrazeneca (AZN), Novartis (NVS), Novo Nordisk A/S (NVO), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to Astrazeneca?

GSK (NYSE:GSK) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

: GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity.
Company Net Margins Return on Equity Return on Assets
GSK 17.82% 44.28% 11.49%
Astrazeneca 17.19% 30.86% 12.68%
: GSK has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.
: In the previous week, Astrazeneca had 25 more articles in the media than GSK. MarketBeat recorded 37 mentions for Astrazeneca and 12 mentions for GSK. Astrazeneca's average media sentiment score of 0.69 beat GSK's score of 0.61 indicating that Astrazeneca is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
7 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Astrazeneca
15 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Positive
: Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GSK $43.07B 2.38 $7.54B $3.85 13.14
Astrazeneca $58.74B 4.88 $10.23B $6.66 27.77
: 15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: GSK currently has a consensus target price of $53.00, indicating a potential upside of 4.81%. Astrazeneca has a consensus target price of $205.33, indicating a potential upside of 11.01%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than GSK.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.90
Astrazeneca
1 Sell rating(s)

0 Hold rating(s)

12 Buy rating(s)

0 Strong Buy rating(s)
2.85
: GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. GSK pays out 48.8% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Astrazeneca	17.19%	30.86%	12.68%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	15 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.38	$7.54B	$3.85	13.14
Astrazeneca	$58.74B	4.88	$10.23B	$6.66	27.77

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Astrazeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Novartis?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

: Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.
Company Net Margins Return on Equity Return on Assets
GSK 17.82% 44.28% 11.49%
Novartis 24.87% 38.82% 15.16%
: GSK has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
: In the previous week, GSK and GSK both had 12 articles in the media. Novartis' average media sentiment score of 1.34 beat GSK's score of 0.61 indicating that Novartis is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
7 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novartis
9 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GSK $43.07B 2.38 $7.54B $3.85 13.14
Novartis $54.53B 5.19 $13.98B $6.98 21.26
: 15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: GSK currently has a consensus target price of $53.00, indicating a potential upside of 4.81%. Novartis has a consensus target price of $141.20, indicating a potential downside of 4.84%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Novartis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.90
Novartis
2 Sell rating(s)

7 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.31
: GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. GSK pays out 48.8% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novartis	24.87%	38.82%	15.16%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.38	$7.54B	$3.85	13.14
Novartis	$54.53B	5.19	$13.98B	$6.98	21.26

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Novartis beats GSK on 12 of the 17 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

: 15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: GSK currently has a consensus target price of $53.00, indicating a potential upside of 4.81%. Novo Nordisk A/S has a consensus target price of $65.56, indicating a potential upside of 43.10%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than GSK.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.90
Novo Nordisk A/S
1 Sell rating(s)

18 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.13
: Novo Nordisk A/S has a net margin of 33.03% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 68.91% beat GSK's return on equity.
Company Net Margins Return on Equity Return on Assets
GSK 17.82% 44.28% 11.49%
Novo Nordisk A/S 33.03% 68.91% 22.86%
: GSK has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
: GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. GSK pays out 48.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 50.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
: In the previous week, Novo Nordisk A/S had 63 more articles in the media than GSK. MarketBeat recorded 75 mentions for Novo Nordisk A/S and 12 mentions for GSK. GSK's average media sentiment score of 0.61 beat Novo Nordisk A/S's score of 0.59 indicating that GSK is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
7 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
32 Very Positive mention(s)
12 Positive mention(s)
17 Neutral mention(s)
4 Negative mention(s)
6 Very Negative mention(s)
Positive
: Novo Nordisk A/S has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GSK $43.07B 2.38 $7.54B $3.85 13.14
Novo Nordisk A/S $46.80B 4.37 $15.51B $3.47 13.20

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novo Nordisk A/S	33.03%	68.91%	22.86%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	32 Very Positive mention(s)	12 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	6 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.38	$7.54B	$3.85	13.14
Novo Nordisk A/S	$46.80B	4.37	$15.51B	$3.47	13.20

Summary

Novo Nordisk A/S beats GSK on 13 of the 18 factors compared between the two stocks.

How does GSK compare to Sanofi?

Sanofi (NASDAQ:SNY) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

: 14.0% of Sanofi shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Sanofi currently has a consensus target price of $51.00, indicating a potential upside of 16.52%. GSK has a consensus target price of $53.00, indicating a potential upside of 4.81%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than GSK.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
1 Sell rating(s)
9 Hold rating(s)

3 Buy rating(s)

2 Strong Buy rating(s)
2.40
GSK
3 Sell rating(s)

5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.90
: GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.
Company Net Margins Return on Equity Return on Assets
Sanofi 16.95% 13.39% 7.58%
GSK 17.82% 44.28% 11.49%
: Sanofi has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
: Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.0%. GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Sanofi pays out 49.4% of its earnings in the form of a dividend. GSK pays out 48.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
: In the previous week, GSK had 3 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for GSK and 9 mentions for Sanofi. GSK's average media sentiment score of 0.61 beat Sanofi's score of 0.18 indicating that GSK is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
GSK
7 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sanofi $49.35B 2.16 $8.84B $3.58 12.23
GSK $43.07B 2.38 $7.54B $3.85 13.14

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
GSK	17.82%	44.28%	11.49%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.16	$8.84B	$3.58	12.23
GSK	$43.07B	2.38	$7.54B	$3.85	13.14

Summary

GSK beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does GSK compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

: GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 2.58%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.
Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical 2.58% 10.60% 5.21%
GSK 17.82% 44.28% 11.49%
: GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Takeda Pharmaceutical $30.09B 1.77 $712.33M $0.24 69.60
GSK $43.07B 2.38 $7.54B $3.85 13.14
: 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, GSK had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for GSK and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.76 beat GSK's score of 0.61 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GSK
7 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Takeda Pharmaceutical has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.
: Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Takeda Pharmaceutical pays out 208.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 48.8% of its earnings in the form of a dividend. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
: GSK has a consensus target price of $53.00, indicating a potential upside of 4.81%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.50
GSK
3 Sell rating(s)

5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.90

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.58%	10.60%	5.21%
GSK	17.82%	44.28%	11.49%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.77	$712.33M	$0.24	69.60
GSK	$43.07B	2.38	$7.54B	$3.85	13.14

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

Summary

GSK beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$102.23B	$3.40B	$6.28B	$22.97B
Dividend Yield	3.73%	2.23%	2.74%	4.03%
P/E Ratio	13.14	38.94	29.18	28.63
Price / Sales	2.38	309.34	507.86	14.77
Price / Cash	8.39	125.30	43.42	25.32
Price / Book	4.37	7.37	9.82	4.65
Net Income	$7.54B	$23.57M	$3.55B	$1.07B
7 Day Performance	-3.49%	4.62%	2.28%	1.25%
1 Month Performance	-9.36%	7.82%	6.43%	7.50%
1 Year Performance	36.27%	82.71%	44.87%	32.80%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.5505 of 5 stars	$50.57 +0.4%	$53.00 +4.8%	+34.9%	$102.23B	$43.07B	13.14	66,841	Dividend Cut
AZN Astrazeneca	3.7277 of 5 stars	$183.27 -0.8%	$205.33 +12.0%	+31.6%	$286.51B	$58.74B	27.52	96,100	Analyst Forecast
NVS Novartis	3.9598 of 5 stars	$144.57 -1.4%	$141.20 -2.3%	+34.0%	$279.68B	$54.53B	20.71	75,267	Positive News
NVO Novo Nordisk A/S	4.7924 of 5 stars	$44.42 +1.2%	$65.56 +47.6%	-30.9%	$195.92B	$46.80B	12.80	69,505	Trending News Gap Up
SNY Sanofi	3.9071 of 5 stars	$43.35 -5.9%	$51.00 +17.6%	-17.6%	$112.39B	$49.35B	12.11	74,846	Ex-Dividend

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors